Kin Ki Jim

Kin Ki Jim

Auto-generated profile, based on publicly available information

Kin Ki Jim

University of Lausanne

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DSDennapa Saeloh
Dennapa Saeloh
VTVaromyalin Tipmanee
Varomyalin Tipmanee
KJKin Ki Jim
Kin Ki Jim
MDMarien P Dekker
Marien P Dekker
WBWilbert Bitter
Wilbert Bitter
LHLeendert Hamoen
Leendert Hamoen
The acylphloroglucinol rhodomyrtone is a promising new antibiotic isolated from the rose myrtle Rhodomyrtus tomentosa, a plant used in Asian traditional medicine. While many studies have demonstrated its antibacterial potential in a variety of clinical applications, very little is known about the mechanism of action of rhodomyrtone. Preceding studies have been focused on intracellular targets, but no specific intracellular protein could be confirmed as main target. Using live cell, high-resolution, and electron microscopy we demonstrate that rhodomyrtone causes large membrane invaginations with a dramatic increase in fluidity, which attract a broad range of membrane proteins. Invaginations then form intracellular vesicles, thereby trapping these proteins. Aberrant protein localization impairs several cellular functions, including the respiratory chain and the ATP synthase complex. Being uncharged and devoid of a particular amphipathic structure, rhodomyrtone did not seem to be a typical membrane-inserting molecule. In fact, molecular dynamics simulations showed that instead of inserting into the bilayer, rhodomyrtone transiently binds to phospholipid head groups and causes distortion of lipid packing, providing explanations for membrane fluidization and induction of membrane curvature. Both its transient binding mode and its ability to form protein-trapping membrane vesicles are unique, making it an attractive new antibiotic candidate with a novel mechanism of action. Bacterial antibiotic resistance constitutes a major public healthcare issue and deaths caused by antimicrobial resistance are expected to soon exceed the number of cancer-related fatalities. In order to fight resistance, new antibiotics have to be developed that are not affected by existing microbial resistance strategies. Thus, antibiotics with novel or multiple targets are urgently needed. Rhodomyrtone displays excellent antibacterial activity, has been safely used in traditional Asian medicine for a long time, and resistance against this promising antibiotic candidate could not be detected in multiple passaging experiments. Here we demonstrate that this rhodomyrtone possesses a completely novel mechanism of action, which is opposed to that of existing cell envelope-targeting drugs, minimizing the risk of cross-resistance, and in fact rhodomyrtone is highly active against e.g. vancomycin-resistant Staphylococcus aureus. Thus, rhodomyrtone is an extremely interesting compound for further antibacterial drug development.

15 December 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
EVErik H. Vogelzang
Erik H. Vogelzang
FLFloris C. Loeff
Floris C. Loeff
NDNinotska I. L. Derksen
Ninotska I. L. Derksen
SKSimone Kruithof
Simone Kruithof
PHPleuni Ooijevaar-De Heer
Pleuni Ooijevaar-De Heer
TRTheo Rispens
Theo Rispens
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only mild disease that may evoke relatively low Ab titers compared with patients admitted to hospitals. Generally, total Ab bridging assays combine good sensitivity with high specificity. Therefore, we developed sensitive total Ab bridging assays for detection of SARS-CoV-2 Abs to the receptor-binding domain (RBD) and nucleocapsid protein in addition to conventional isotype-specific assays. Ab kinetics was assessed in PCR-confirmed, hospitalized coronavirus disease 2019 (COVID-19) patients (n = 41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confirmed hospital care workers (n = 47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n = 14). In nonhospitalized patients, the Ab response to RBD is weaker but follows similar kinetics, as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19–suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; nucleocapsid protein Abs emerged less consistently. Furthermore, we demonstrated the feasibility of finger-prick sampling for Ab detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 Abs in hospitalized and nonhospitalized patients and are therefore well suited to conduct seroprevalence studies. Key Points We developed a sensitive total Ab bridging assay to detect SARS-CoV-2 Abs. The assay reliably detects SARS-CoV-2 Abs also in nonhospitalized patients. Fewer Abs arise but with similar kinetics compared with hospitalized patients.

14 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBevika Sewgoolam
Bevika Sewgoolam
KJKin Ki Jim
Kin Ki Jim
VBVincent de Bakker
Vincent de Bakker
FBFlorian P. Bock
Florian P. Bock
PGPaddy S. Gibson
Paddy S. Gibson
JVJan-Willem Veening
Jan-Willem Veening
Streptococcus pneumoniae is a human pathogen that has become increasingly resistant to synthetic fluoroquinolone antibiotics that target bacterial topoisomerases. To identify pathways essential under fluoroquinolone stress and potential novel targets to revitalize use of this antibiotic class, we perform genome-wide CRISPRi-seq screens and generate antibiotic-gene essentiality signatures. Expectedly, genes involved in DNA recombination and repair become more important under fluoroquinolone-induced DNA damage, including recA, recJ, recF, recO, rexAB, and ruvAB. Surprisingly, specific downregulation of the gene encoding the histidine kinase LiaS caused fluoroquinolone hypersensitivity. LiaS is part of the LiaFSR (VraTSR) three-component regulatory system involved in cell envelope homeostasis. We show that LiaS keeps the response regulator LiaR inactive, and that liaS deletion causes LiaR hyperphosphorylation and upregulation of the LiaR regulon. We use RNA-seq to refine the LiaR regulon, highlighting the role of heat-shock response and pleiotropic regulator SpxA2 in fluoroquinolone sensitivity. Activating the LiaR-regulon by the cell envelope-targeting antibiotic bacitracin synergized with ciprofloxacin and levofloxacin, restoring sensitivity in fluoroquinolone-resistant strains in vitro. Furthermore, bacitracin/levofloxacin combination therapy is effective in vivo and improved treatment of fluoroquinolone-resistant S. pneumoniae infection in a zebrafish meningitis model. These findings offer a starting point for identification and validation of potent combination therapies to treat antibiotic-resistant pneumococcal infections.

11 January 2024 in Biology Methods and Protocols
Verified
Journal Article
Open access
PDF file
RBRinie van Beuningen
Rinie van Beuningen
KJKin Ki Jim
Kin Ki Jim
MBMaikel Boot
Maikel Boot
MOMichel Ossendrijver
Michel Ossendrijver
BKBart J.F. Keijser
Bart J.F. Keijser
TKTim Kievits
Tim Kievits
The coronavirus disease 2019 (COVID-19) pandemic underscored the necessity for rapid and efficient diagnostic testing to mitigate outbreaks and control disease transmission. While real-time reverse transcriptase quantitative PCR (RT-qPCR) has been the gold standard due to its high sensitivity and specificity, its logistical complexities and extended turnaround times highlighted the need for alternative molecular methods and non-standard equipment and consumables not subject to supply chain pressure. Loop-mediated isothermal amplification (LAMP) offers several advantages over RT-qPCR, including faster processing time, assay flexibility and cost-effectiveness. During the pandemic, LAMP was successfully demonstrated as a viable alternative to RT-qPCR for SARS-Related Coronavirus 2 detection. However, due to a 100 to 1,000-fold increase in testing volumes, there was an imminent need for automating and scaling up existing LAMP testing workflows leveraging a robotic infrastructure, while retaining analytical performance and cost-effectiveness. In 2020, the Foundation TOMi started the “TOMi corona initiative” to develop and validate a high-throughput, end-to-end, automated, scalable single-step RNA purification, and LAMP-based COVID-19 testing system called SMART-LAMP (Scalable Molecular Automation for Rapid Testing using LAMP) that can process up to 40,000 samples per day using existing laboratory equipment infrastructure with sensitivity comparable to RT-qPCR. This system provides a rapid and scalable diagnostic solution for future pandemics, capable of processing over 40,000 samples per day. In addition, the system is designed to minimize consumable costs and reduces the overall use of plastics to align with increasingly strict sustainability goals that will be imposed over the coming years. Importantly, this system and public–private partnerships in the TOMi corona initiative has the potential to serve as a baseline to enhance pandemic preparedness and response capabilities.

19 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
EVErik H. Vogelzang
Erik H. Vogelzang
FLFloris C. Loeff
Floris C. Loeff
NDNinotska Il Derksen
Ninotska Il Derksen
SKSimone Kruithof
Simone Kruithof
PHPleuni Ooijevaar-De Heer
Pleuni Ooijevaar-De Heer
TRTheo Rispens
Theo Rispens
SARS-CoV-2 infections often cause only mild disease that may evoke relatively low antibody titers compared to patients admitted to hospitals. Generally, total antibody bridging assays combine good sensitivity with high selectivity. Therefore, we developed sensitive total antibody bridging assays for detection of SARS-CoV-2 antibodies to the receptor-binding domain (RBD) and nucleocapsid protein (NP), in addition to conventional isotype-specific assays. Antibody kinetics was assessed in PCR-confirmed hospitalized COVID-19 patients (n=41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n=182), PCR-confirmed hospital care workers (n=47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n=14). In non-hospitalized patients, the antibody response to RBD is weaker but follows similar kinetics as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; NP antibodies emerged less consistently. Furthermore, we demonstrated the feasibility of finger prick sampling for antibody detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 antibodies in hospitalized and non-hospitalized patients, and are therefore well-suited to conduct seroprevalence studies.

4 April 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MBMatthijs C. Brouwer
Matthijs C. Brouwer
KJKin K. Jim
Kin K. Jim
KBKimberley S. Benschop
Kimberley S. Benschop
KWKatja C. Wolthers
Katja C. Wolthers
AEArie van der Ende
Arie van der Ende
DBDiekerik van de Beek
Diekerik van de Beek
To the Editor—Bacterial meningitis is a severe disease with substantial mortality and morbidity despite the availability of effective antimicrobial agents and adjunctive therapies [1, 2]. Recently, a study involving adults with community-acquired bacterial meningitis in Malawi showed that coinfection with Epstein Barr Virus (EBV) occurred in 79 of 149 bacterial meningitis patients (53%) and that EBV load was associated with higher mortality [3]. Coinfection with cytomegalovirus (CMV) was detected in 7% of patients. A high proportion of patients (77%) in this study were human immunodeficiency virus (HIV) positive, which was found to have a strong influence on the rate of coinfection with EBV and CMV. The aim of the current study was to establish whether herpes viruses and other neurotropic viruses could be detected in the cerebrospinal fluid (CSF) of adult bacterial meningitis patients in a Dutch population with a low HIV infection rate.